海正药业子公司依维莫司原料药获得CEP证书

Core Viewpoint - Haizheng Pharmaceutical's subsidiary, Haizheng Hangzhou Company, has received the Certificate of Suitability to Monograph of European Pharmacopoeia (CEP) for its active pharmaceutical ingredient, Everolimus, indicating recognition of its quality in the European market and enhancing its qualifications for international market expansion [1] Group 1 - Haizheng Hangzhou Company has been awarded the CEP certificate by the European Directorate for the Quality of Medicines & HealthCare (EDQM) [1] - The CEP certification signifies that the quality of Everolimus meets European standards, allowing the product to enter the EU and other markets that recognize the CEP certificate [1] - This certification is expected to have a positive impact on the company's efforts to expand its international market presence [1]